Atrasentan in Patients (Pts) with IgAN from East (E) Asia: Phase 3 ALIGN Final Data (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0652; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; P3 | "Fluid retention adverse events occurred in 7 (10.3%) pts on atrasentan vs 4 (5.7%) on placebo; none led to discontinuation. Conclusion These results in pts from E Asia are consistent with the overall ALIGN population showing that 2.5 years of atrasentan treatment preserves kidney function and is well tolerated with a consistent safety profile."
Clinical • P3 data • Glomerulonephritis • IgA Nephropathy • Renal Disease
|
|
Hong Zhang; Sangho Lee; Fan Fan Hou; Vincent Wu; Sydney Tang; Hiddo Jan L. Heerspink; Jonathan Barratt; Meg Jardine; Donald E. Kohan; Richard A. Lafayette; Adeera Levin; Suparna Mallik; Yuhan Li; Amit Lodha; Dmitrij Kollins; Adrian Liew
|